182 related articles for article (PubMed ID: 24801119)
1. Randomised study of a bioabsorbable polymer-coated sirolimus-eluting stent: results of the DESSOLVE II trial.
Wijns W; Vrolix M; Verheye S; Schoors D; Slagboom T; Gosselink M; Benit E; Donohoe D; Knape C; Attizzani GF; Lansky AJ; Ormiston J;
EuroIntervention; 2015 Apr; 10(12):1383-90. PubMed ID: 24801119
[TBL] [Abstract][Full Text] [Related]
2. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
[TBL] [Abstract][Full Text] [Related]
3. Drug-eluting stent implantation in patients with acute coronary syndrome - the Activity of Platelets after Inhibition and Cardiovascular Events: Optical Coherence Tomography (APICE OCT) study.
Chieffo A; Buchanan GL; Parodi G; Versaci F; Bianchi RM; Valenti R; Saccà S; Mongiardo A; Span S; Migliorini A; Spaccarotella C; Reimers B; Antoniucci D; Indolfi C; Ferrari A; Maehara A; Mintz GS; Colombo A
EuroIntervention; 2014 Dec; 10(8):916-23. PubMed ID: 24974806
[TBL] [Abstract][Full Text] [Related]
4. Bioabsorbable polymer-coated sirolimus-eluting stent implantation preserves coronary vasomotion: A DESSOLVE II trial sub-study.
Rusinaru D; Vrolix M; Verheye S; Chowdhary S; Schoors D; Di Mario C; Desmet W; Donohoe DJ; Ormiston JA; Knape C; Bezerra H; Lansky A; Wijns W;
Catheter Cardiovasc Interv; 2015 Dec; 86(7):1141-50. PubMed ID: 25044635
[TBL] [Abstract][Full Text] [Related]
5. A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial.
Gao RL; Xu B; Lansky AJ; Yang YJ; Ma CS; Han YL; Chen SL; Li H; Zhang RY; Fu GS; Yuan ZY; Jiang H; Huo Y; Li W; Zhang YJ; Leon MB;
EuroIntervention; 2013 May; 9(1):75-83. PubMed ID: 23685298
[TBL] [Abstract][Full Text] [Related]
6. Neointimal coverage of zotarolimus-eluting stent at 1, 2, and 3 months' follow-up: an optical coherence tomography study.
Hashikata T; Tojo T; Namba S; Kitasato L; Hashimoto T; Kameda R; Shimohama T; Yamaoka-Tojo M; Ako J
Heart Vessels; 2016 Feb; 31(2):206-11. PubMed ID: 25362579
[TBL] [Abstract][Full Text] [Related]
7. Comparison of early strut coverage between zotarolimus- and everolimus-eluting stents using optical coherence tomography.
Kim S; Kim JS; Shin DH; Kim BK; Ko YG; Choi D; Cho YK; Nam CW; Hur SH; Jang Y; Hong MK
Am J Cardiol; 2013 Jan; 111(1):1-5. PubMed ID: 23040589
[TBL] [Abstract][Full Text] [Related]
8. First-in-man study evaluating the safety and efficacy of a second generation biodegradable polymer sirolimus-eluting stent in the treatment of patients with de novo coronary lesions: clinical, Angiographic, and OCT outcomes of CREDIT-1.
Wang G; Sun Z; Jin Q; Xu K; Li Y; Wang X; Ma Y; Liu H; Zhao X; Wang B; Deng J; Guan S; Ge M; Wang X; Xu B; Han Y
Catheter Cardiovasc Interv; 2015 Mar; 85 Suppl 1():744-51. PubMed ID: 25630447
[TBL] [Abstract][Full Text] [Related]
9. Late lumen loss and intima hyperplasia after sirolimus-eluting and zotarolimus-eluting stent implantation in diabetic patients: the diabetes and drug-eluting stent (DiabeDES III) angiography and intravascular ultrasound trial.
Jensen LO; Maeng M; Thayssen P; Villadsen A; Krusell L; Botker HE; Pedersen KE; Aaroe J; Christiansen EH; Vesterlund T; Hansen KN; Ravkilde J; Tilsted HH; Lassen JF; Thuesen L
EuroIntervention; 2011 Jul; 7(3):323-31. PubMed ID: 21729834
[TBL] [Abstract][Full Text] [Related]
10. Evaluation in 3 months duration of neointimal coverage after zotarolimus-eluting stent implantation by optical coherence tomography: the ENDEAVOR OCT trial.
Kim JS; Jang IK; Fan C; Kim TH; Kim JS; Park SM; Choi EY; Lee SH; Ko YG; Choi D; Hong MK; Jang Y
JACC Cardiovasc Interv; 2009 Dec; 2(12):1240-7. PubMed ID: 20129551
[TBL] [Abstract][Full Text] [Related]
11. Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
Kandzari DE; Mauri L; Popma JJ; Turco MA; Gurbel PA; Fitzgerald PJ; Leon MB
JACC Cardiovasc Interv; 2011 May; 4(5):543-50. PubMed ID: 21596327
[TBL] [Abstract][Full Text] [Related]
12. A sirolimus-eluting bioabsorbable polymer-coated stent (MiStent) versus an everolimus-eluting durable polymer stent (Xience) after percutaneous coronary intervention (DESSOLVE III): a randomised, single-blind, multicentre, non-inferiority, phase 3 trial.
de Winter RJ; Katagiri Y; Asano T; Milewski KP; Lurz P; Buszman P; Jessurun GAJ; Koch KT; Troquay RPT; Hamer BJB; Ophuis TO; Wöhrle J; Wyderka R; Cayla G; Hofma SH; Levesque S; Żurakowski A; Fischer D; Kośmider M; Goube P; Arkenbout EK; Noutsias M; Ferrari MW; Onuma Y; Wijns W; Serruys PW
Lancet; 2018 Feb; 391(10119):431-440. PubMed ID: 29203070
[TBL] [Abstract][Full Text] [Related]
13. Optical coherence tomography study of healing characteristics of paclitaxel-eluting balloons vs. everolimus-eluting stents for in-stent restenosis: the SEDUCE (Safety and Efficacy of a Drug elUting balloon in Coronary artery rEstenosis) randomised clinical trial.
Adriaenssens T; Dens J; Ughi G; Bennett J; Dubois C; Sinnaeve P; Wiyono S; Coosemans M; Belmans A; D'hooge J; Vrolix M; Desmet W
EuroIntervention; 2014 Aug; 10(4):439-48. PubMed ID: 25138182
[TBL] [Abstract][Full Text] [Related]
14. A first-in-man clinical evaluation of Ultimaster, a new drug-eluting coronary stent system: CENTURY study.
Barbato E; Salinger-Martinovic S; Sagic D; Beleslin B; Vrolix M; Neskovic AN; Jagic N; Verheye S; Mehmedbegovic Z; Wijns W
EuroIntervention; 2015 Sep; 11(5):541-8. PubMed ID: 25136883
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the Absorbable Polymer Sirolimus-Eluting Stent (MiStent) to the Durable Polymer Everolimus-Eluting Stent (Xience) (from the DESSOLVE I/II and ISAR-TEST-4 Studies).
Lansky AJ; Kastrati A; Edelman ER; Parise H; Ng VG; Ormiston J; Wijns W; Byrne RA
Am J Cardiol; 2016 Feb; 117(4):532-538. PubMed ID: 26762729
[TBL] [Abstract][Full Text] [Related]
16. Early neointimal coverage and vasodilator response following biodegradable polymer sirolimus-eluting vs. durable polymer zotarolimus-eluting stents in patients with acute coronary syndrome –HATTRICK-OCT trial.
Karjalainen PP; Varho V; Nammas W; Mikkelsson J; Pietilä M; Ylitalo A; Airaksinen JK; Sia J; Nyman K; Biancari F; Kiviniemi T
Circ J; 2015; 79(2):360-7. PubMed ID: 25502167
[TBL] [Abstract][Full Text] [Related]
17. Safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de-novo coronary artery lesions (BIOSOLVE-II): 6 month results of a prospective, multicentre, non-randomised, first-in-man trial.
Haude M; Ince H; Abizaid A; Toelg R; Lemos PA; von Birgelen C; Christiansen EH; Wijns W; Neumann FJ; Kaiser C; Eeckhout E; Lim ST; Escaned J; Garcia-Garcia HM; Waksman R
Lancet; 2016 Jan; 387(10013):31-9. PubMed ID: 26470647
[TBL] [Abstract][Full Text] [Related]
18. Elutax paclitaxel-eluting balloon followed by bare-metal stent compared with Xience V drug-eluting stent in the treatment of de novo coronary stenosis: a randomized trial.
Liistro F; Porto I; Angioli P; Grotti S; Ducci K; Falsini G; Bolognese L
Am Heart J; 2013 Nov; 166(5):920-6. PubMed ID: 24176449
[TBL] [Abstract][Full Text] [Related]
19. First-in-man randomised comparison of the BuMA Supreme biodegradable polymer sirolimus-eluting stent versus a durable polymer zotarolimus-eluting coronary stent: the PIONEER trial.
von Birgelen C; Asano T; Amoroso G; Aminian A; Brugaletta S; Vrolix M; Hernandez-Antolín R; van de Harst P; Iñiguez A; Janssens L; Smits PC; Wykrzykowska JJ; Ribeiro VG; Pereira H; da Silva PC; Piek JJ; Onuma Y; Serruys PW; Sabaté M
EuroIntervention; 2018 Apr; 13(17):2026-2035. PubMed ID: 28923787
[TBL] [Abstract][Full Text] [Related]
20. Angiographic outcomes of Orsiro biodegradable polymer sirolimus-eluting stents and Resolute Integrity durable polymer zotarolimus-eluting stents: results of the ORIENT trial.
Kang SH; Chung WY; Lee JM; Park JJ; Yoon CH; Suh JW; Cho YS; Doh JH; Cho JM; Bae JW; Youn TJ; Chae IH
EuroIntervention; 2017 Jan; 12(13):1623-1631. PubMed ID: 28105994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
